A5059792318- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Head and Neck Cancer Studies
- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- Radiomics and Machine Learning in Medical Imaging
- Advanced Breast Cancer Therapies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Advances in Oncology and Radiotherapy
- Medical Imaging Techniques and Applications
- Statistical Methods in Clinical Trials
- Radiopharmaceutical Chemistry and Applications
- Urological Disorders and Treatments
- Breast Cancer Treatment Studies
- Effects of Radiation Exposure
- Genital Health and Disease
- Radiation Therapy and Dosimetry
- Esophageal Cancer Research and Treatment
Institute of Cancer Research
2016-2025
Skåne University Hospital
2025
Lund University
2025
Nordland Hospital
2025
Cancer Research UK
2005-2024
TESLA (Czechia)
2024
Lancashire Teaching Hospitals NHS Foundation Trust
2009-2024
Arcadia
2024
University of Central Lancashire
2024
University of Glasgow
2024
Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition olaparib.
Tamoxifen, taken for five years, is the standard adjuvant treatment postmenopausal women with primary, estrogen-receptor-positive breast cancer. Despite this treatment, however, some patients have a relapse.We conducted double-blind, randomized trial to test whether, after two three years of tamoxifen therapy, switching exemestane was more effective than continuing therapy remainder treatment. The primary end point disease-free survival.Of 4742 enrolled, 2362 were randomly assigned switch...
Xerostomia is the most common late side-effect of radiotherapy to head and neck. Compared with conventional radiotherapy, intensity-modulated (IMRT) can reduce irradiation parotid glands. We assessed hypothesis that parotid-sparing IMRT reduces incidence severe xerostomia.We undertook a randomised controlled trial between Jan 21, 2003, Dec 7, 2007, compared (control) IMRT. randomly assigned patients histologically confirmed pharyngeal squamous-cell carcinoma (T1-4, N0-3, M0) at six UK...
<h3>Abstract</h3> <b>Objective</b> : To assess the risk of death associated20with various patterns alcohol consumption. Design - Prospective study mortality in relation to drinking habits 1978, with causes sought over next 13 years (to 1991). <b>Subjects</b> 12 321 British male doctors born between 1900 and 1930 (mean 1916) who replied a postal questionnaire 1978. Those written 1978 were survivors long running prospective effects smoking that had begun 195120and was still continuing. Results...
BackgroundProstate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We present pre-planned analysis of the efficacy and side-effects randomised trial comparing conventional radiotherapy after 5 years follow-up.MethodsCHHiP is randomised, phase 3, non-inferiority recruited men with localised prostate (pT1b–T3aN0M0). Patients were randomly assigned (1:1:1) (74 Gy delivered in 37 fractions over 7·4 weeks) or one two...
Radiotherapy is an alternative to cystectomy in patients with muscle-invasive bladder cancer. In other disease sites, synchronous chemoradiotherapy has been associated increased local control and improved survival, as compared radiotherapy alone.
BackgroundMetastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the association between DDR aberrations and olaparib metastatic cancer.MethodsIn this open-label, investigator-initiated, randomised phase 2 following a selection (or pick-the-winner) design, we recruited participants from 17 UK hospitals. Men aged 18 years or older with progressing previously treated one two taxane...
Intermittent androgen deprivation for prostate-specific antigen (PSA) elevation after radiotherapy may improve quality of life and delay hormone resistance. We assessed overall survival with intermittent versus continuous in a noninferiority randomized trial.
BackgroundLocalised prostate cancer is commonly treated with external-beam radiotherapy. Moderate hypofractionation has been shown to be non-inferior conventional fractionation. Ultra-hypofractionated stereotactic body radiotherapy would allow shorter treatment courses but could increase acute toxicity compared conventionally fractionated or moderately hypofractionated We report the findings from a randomised trial of standard-of-care versus five-fraction for low-risk intermediate-risk...
BackgroundUrothelial carcinomas of the upper urinary tract (UTUCs) are rare, with poorer stage-for-stage prognosis than urothelial bladder. No international consensus exists on benefit adjuvant chemotherapy for patients UTUCs after nephroureterectomy curative intent. The POUT (Peri-Operative versus sUrveillance in Tract cancer) trial aimed to assess efficacy systemic platinum-based UTUCs.MethodsWe did a phase 3, open-label, randomised controlled at 71 hospitals UK. We recruited UTUC staged...
Abstract Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib cancer, demonstrating antitumor activity associating with homologous recombination DNA repair defects. now report targeted and whole-exome sequencing serial circulating cell-free (cfDNA) samples collected during this trial. Decreases cfDNA concentration independently associated outcome multivariable analyses (HR overall...
Prostate cancer might have high radiation-fraction sensitivity, implying a therapeutic advantage of hypofractionated treatment. We present pre-planned preliminary safety analysis side-effects in stages 1 and 2 randomised trial comparing standard radiotherapy.We did multicentre, study recruited men with localised prostate between Oct 18, 2002, Aug 12, 2006, at 11 UK centres. Patients were randomly assigned 1:1:1 ratio to receive conventional or high-dose intensity-modulated radiotherapy, all...
The genomics of primary prostate cancer differ from those metastatic castration-resistant (mCRPC). We studied genomic aberrations in biopsies patients who developed mCRPC, also studying matching, same-patient, diagnostic, and mCRPC following treatment. profiled 470 treatment-naive diagnostic and, for 61 cases, biopsies, using targeted low-pass whole-genome sequencing (n = 52). Descriptive statistics were used to summarize mutation copy number profile. Prevalence was compared Fisher's exact...
Several studies have reported associations between radiation toxicity and single nucleotide polymorphisms (SNPs) in candidate genes. Few been tested independent validation studies. This prospective study aimed to validate genotype a large dataset.92 (of 98 attempted) SNPs 46 genes were successfully genotyped 1613 patients: 976 received adjuvant breast radiotherapy the Cambridge IMRT trial (ISRCTN21474421, n=942) or of at Christie Hospital, Manchester, UK (n=34). A further 637 radical...
Abstract PARP inhibitors are approved for treating advanced prostate cancers (APC) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers warranted. Herein we analyzed TOPARP-B phase II clinical trial samples, evaluating whole-exome and low-pass whole-genome sequencing IHC IF assays ATM RAD51 foci (testing homologous recombination function). BRCA1/2 germline somatic pathogenic mutations associated similar benefit from olaparib; greater...
BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer (MIBC), demonstrated improvement in locoregional control by adding fluorouracil and mitomycin C to radiotherapy (James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy cancer. N Engl J Med 2012;366:1477-88). There are limited data on long-term recurrence risk.
<h2>Summary</h2><h3>Background</h3> Most newly diagnosed oropharyngeal and hypopharyngeal cancers are treated with chemoradiotherapy curative intent but at the consequence of adverse effects on quality life. We aimed to investigate if dysphagia-optimised intensity-modulated radiotherapy (DO-IMRT) reduced radiation dose dysphagia aspiration related structures improved swallowing function compared standard IMRT. <h3>Methods</h3> DARS was a parallel-group, phase 3, multicentre, randomised,...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. POUT was a phase III, randomized, open-label trial, including 261 patients with muscle-invasive lymph...
Whether stereotactic body radiotherapy (SBRT) is noninferior to conventionally or moderately hypofractionated regimens with respect biochemical clinical failure in patients localized prostate cancer unclear.